TNIK (TRAF2 and NCK interacting kinase) is a serine/threonine kinase functioning as a critical regulator of multiple signaling pathways with broad tissue distribution. Mechanistically, TNIK activates Wnt/β-catenin signaling by phosphorylating TCF4 and forming a regulatory complex with β-catenin and TRAF2 12. TNIK also phosphorylates ERM proteins to regulate endothelial barrier integrity and inflammatory responses 3, and activates the Hippo pathway through LATS1/2 phosphorylation, contributing to organ size control and tumor suppression 4. Additionally, TNIK modulates cytoskeletal dynamics and neuronal dendrite morphogenesis 5. Disease relevance spans multiple conditions. TNIK aberrant expression drives colorectal and other malignancies through dysregulated Wnt signaling 1, while TNIK upregulation in failed-repair proximal tubule cells following acute kidney injury promotes epithelial cell survival and suppresses inflammation 6. Mutations in TNIK associate with autosomal recessive intellectual developmental disorder 54. Clinically, rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and tolerability in phase I trials 7 and showed promising efficacy in phase 2a testing for idiopathic pulmonary fibrosis, with the 60 mg daily dose producing a mean forced vital capacity increase of +98.4 ml 8. These results indicate TNIK inhibition may effectively target fibrotic and inflammatory diseases.